BACKGROUND: The presence of minimal residual disease detected by polymerase chain reaction techniques prior to allogeneic hematopoietic stem cell transplantation has proven to be an independent prognostic factor for poor outcome in children with acute lymphoblastic leukemia. DESIGN AND METHODS: The aim of this study was to ascertain whether the presence of minimal residual disease detected by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation is related to outcome in children acute lymphoblastic leukemia. Minimal residual disease was quantified by multiparametric flow cytometry at a median of 10 days prior to hematopoietic stem cell transplantation in 31 children (age range, 10 months to 16 years) with acute lymphoblastic leukemia. Thirteen patients were transplanted in first remission. Stem cell donors were HLA-identical siblings in 8 cases and matched unrelated donors in 23. Twenty-six children received a total body irradiation-containing conditioning regimen. According to the level of minimal residual disease, patients were divided into two groups: minimal residual disease-positive (>or=0.01%) (n=10) and minimal residual disease-negative (<0.01%) (n=21). RESULTS: Estimated event-free survival rates at 2 years for the minimal residual disease-negative and -positive subgroups were 74% and 20%, respectively (P=0.004) and overall survival rates were 80% and 20%, respectively (P=0.005). Bivariate analysis identified pre-transplant minimal residual disease as the only significant factor for relapse and also for death (P<0.01). CONCLUSIONS: The presence of minimal residual disease measured by multiparametric flow cytometry identified a group of patients with a 9.5-fold higher risk of relapse and a 3.2-fold higher risk of death than those without minimal residual disease. This study supports the strong relationship between pre-transplantation minimal residual disease measured by multiparametric flow cytometry and outcome following allogeneic hematopoietic stem cell transplantation and concur with the results of previous studies using polymerase chain reaction techniques.
BACKGROUND: The presence of minimal residual disease detected by polymerase chain reaction techniques prior to allogeneic hematopoietic stem cell transplantation has proven to be an independent prognostic factor for poor outcome in children with acute lymphoblastic leukemia. DESIGN AND METHODS: The aim of this study was to ascertain whether the presence of minimal residual disease detected by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation is related to outcome in childrenacute lymphoblastic leukemia. Minimal residual disease was quantified by multiparametric flow cytometry at a median of 10 days prior to hematopoietic stem cell transplantation in 31 children (age range, 10 months to 16 years) with acute lymphoblastic leukemia. Thirteen patients were transplanted in first remission. Stem cell donors were HLA-identical siblings in 8 cases and matched unrelated donors in 23. Twenty-six children received a total body irradiation-containing conditioning regimen. According to the level of minimal residual disease, patients were divided into two groups: minimal residual disease-positive (>or=0.01%) (n=10) and minimal residual disease-negative (<0.01%) (n=21). RESULTS: Estimated event-free survival rates at 2 years for the minimal residual disease-negative and -positive subgroups were 74% and 20%, respectively (P=0.004) and overall survival rates were 80% and 20%, respectively (P=0.005). Bivariate analysis identified pre-transplant minimal residual disease as the only significant factor for relapse and also for death (P<0.01). CONCLUSIONS: The presence of minimal residual disease measured by multiparametric flow cytometry identified a group of patients with a 9.5-fold higher risk of relapse and a 3.2-fold higher risk of death than those without minimal residual disease. This study supports the strong relationship between pre-transplantation minimal residual disease measured by multiparametric flow cytometry and outcome following allogeneic hematopoietic stem cell transplantation and concur with the results of previous studies using polymerase chain reaction techniques.
Authors: E Coustan-Smith; F G Behm; J Sanchez; J M Boyett; M L Hancock; S C Raimondi; J E Rubnitz; G K Rivera; J T Sandlund; C H Pui; D Campana Journal: Lancet Date: 1998-02-21 Impact factor: 79.321
Authors: Gunter Kerst; Hermann Kreyenberg; Carmen Roth; Catrin Well; Klaus Dietz; Elaine Coustan-Smith; Dario Campana; Ewa Koscielniak; Charlotte Niemeyer; Paul G Schlegel; Ingo Müller; Dietrich Niethammer; Peter Bader Journal: Br J Haematol Date: 2005-03 Impact factor: 6.998
Authors: C J Knechtli; N J Goulden; J P Hancock; V L Grandage; E L Harris; R J Garland; C G Jones; A W Rowbottom; L P Hunt; A F Green; E Clarke; A W Lankester; J M Cornish; D H Pamphilon; C G Steward; A Oakhill Journal: Blood Date: 1998-12-01 Impact factor: 22.113
Authors: Lucie Sramkova; Katerina Muzikova; Eva Fronkova; Ondrej Krejci; Petr Sedlacek; Renata Formankova; Ester Mejstrikova; Jan Stary; Jan Trka Journal: Pediatr Blood Cancer Date: 2007-01 Impact factor: 3.167
Authors: Michael A Pulsipher; Bryan Langholz; Donna A Wall; Kirk R Schultz; Nancy Bunin; William L Carroll; Elizabeth Raetz; Sharon Gardner; Julie M Gastier-Foster; Denise Howrie; Rakesh K Goyal; James G Douglas; Michael Borowitz; Yvonne Barnes; David T Teachey; Candace Taylor; Stephan A Grupp Journal: Blood Date: 2014-02-04 Impact factor: 22.113